[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Report 2018

March 2018 | 113 pages | ID: A11FAC9D5D9QEN
QYResearch

US$ 4,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the Asia-Pacific Relapsed Acute Myeloid Leukemia Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Relapsed Acute Myeloid Leukemia Drug for these regions, from 2013 to 2025 (forecast), including
  • China
  • Japan
  • South Korea
  • Taiwan
  • India
  • Southeast Asia
  • Australia
Asia-Pacific Relapsed Acute Myeloid Leukemia Drug market competition by top manufacturers/players, with Relapsed Acute Myeloid Leukemia Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • 4SC AG
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • BioLineRx, Ltd.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Cornerstone Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into
  • aNK Program
  • AT-9283
  • BI-836858
  • binimetinib
  • BL-8040
  • Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Clinic
  • Hospital
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Report 2018

1 RELAPSED ACUTE MYELOID LEUKEMIA DRUG OVERVIEW

1.1 Product Overview and Scope of Relapsed Acute Myeloid Leukemia Drug
1.2 Classification of Relapsed Acute Myeloid Leukemia Drug by Product Category
  1.2.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size (Sales) Comparison by Types (2013-2025)
  1.2.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size (Sales) Market Share by Type (Product Category) in 2017
  1.2.3 aNK Program
  1.2.4 AT-9283
  1.2.5 BI-836858
  1.2.6 binimetinib
  1.2.7 BL-8040
  1.2.8 Others
1.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market by Application/End Users
  1.3.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales (Volume) and Market Share Comparison by Applications (2013-2025)
  1.3.2 Clinic
  1.3.3 Hospital
  1.3.4 Others
1.4 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market by Region
  1.4.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 China Status and Prospect (2013-2025)
  1.4.3 Japan Status and Prospect (2013-2025)
  1.4.4 South Korea Status and Prospect (2013-2025)
  1.4.5 Taiwan Status and Prospect (2013-2025)
  1.4.6 India Status and Prospect (2013-2025)
  1.4.7 Southeast Asia Status and Prospect (2013-2025)
  1.4.8 Australia Status and Prospect (2013-2025)
1.5 Asia-Pacific Market Size (Value and Volume) of Relapsed Acute Myeloid Leukemia Drug (2013-2025)
  1.5.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2013-2025)
  1.5.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2025)

2 ASIA-PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG COMPETITION BY PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Competition by Players/Suppliers
  2.1.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share of Key Players/Suppliers (2013-2018)
  2.1.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Share by Players/Suppliers (2013-2018)
2.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug (Volume and Value) by Type
  2.2.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Type (2013-2018)
  2.2.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Type (2013-2018)
2.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug (Volume) by Application
2.4 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug (Volume and Value) by Region
  2.4.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Region (2013-2018)
  2.4.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Region (2013-2018)

3 CHINA RELAPSED ACUTE MYELOID LEUKEMIA DRUG (VOLUME, VALUE AND SALES PRICE)

3.1 China Relapsed Acute Myeloid Leukemia Drug Sales and Value (2013-2018)
  3.1.1 China Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate (2013-2018)
  3.1.2 China Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2018)
  3.1.3 China Relapsed Acute Myeloid Leukemia Drug Sales Price Trend (2013-2018)
3.2 China Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Type
3.3 China Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Application

4 JAPAN RELAPSED ACUTE MYELOID LEUKEMIA DRUG (VOLUME, VALUE AND SALES PRICE)

4.1 Japan Relapsed Acute Myeloid Leukemia Drug Sales and Value (2013-2018)
  4.1.1 Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate (2013-2018)
  4.1.2 Japan Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2018)
  4.1.3 Japan Relapsed Acute Myeloid Leukemia Drug Sales Price Trend (2013-2018)
4.2 Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Type
4.3 Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Application

5 SOUTH KOREA RELAPSED ACUTE MYELOID LEUKEMIA DRUG (VOLUME, VALUE AND SALES PRICE)

5.1 South Korea Relapsed Acute Myeloid Leukemia Drug Sales and Value (2013-2018)
  5.1.1 South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate (2013-2018)
  5.1.2 South Korea Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2018)
  5.1.3 South Korea Relapsed Acute Myeloid Leukemia Drug Sales Price Trend (2013-2018)
5.2 South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Type
5.3 South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Application

6 TAIWAN RELAPSED ACUTE MYELOID LEUKEMIA DRUG (VOLUME, VALUE AND SALES PRICE)

6.1 Taiwan Relapsed Acute Myeloid Leukemia Drug Sales and Value (2013-2018)
  6.1.1 Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate (2013-2018)
  6.1.2 Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2018)
  6.1.3 Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Price Trend (2013-2018)
6.2 Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Type
6.3 Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Application

7 INDIA RELAPSED ACUTE MYELOID LEUKEMIA DRUG (VOLUME, VALUE AND SALES PRICE)

7.1 India Relapsed Acute Myeloid Leukemia Drug Sales and Value (2013-2018)
  7.1.1 India Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate (2013-2018)
  7.1.2 India Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2018)
  7.1.3 India Relapsed Acute Myeloid Leukemia Drug Sales Price Trend (2013-2018)
7.2 India Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Type
7.3 India Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Application

8 SOUTHEAST ASIA RELAPSED ACUTE MYELOID LEUKEMIA DRUG (VOLUME, VALUE AND SALES PRICE)

8.1 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales and Value (2013-2018)
  8.1.1 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate (2013-2018)
  8.1.2 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2018)
  8.1.3 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Price Trend (2013-2018)
8.2 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Type
8.3 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Application

9 AUSTRALIA RELAPSED ACUTE MYELOID LEUKEMIA DRUG (VOLUME, VALUE AND SALES PRICE)

9.1 Australia Relapsed Acute Myeloid Leukemia Drug Sales and Value (2013-2018)
  9.1.1 Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate (2013-2018)
  9.1.2 Australia Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2013-2018)
  9.1.3 Australia Relapsed Acute Myeloid Leukemia Drug Sales Price Trend (2013-2018)
9.2 Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Type
9.3 Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume and Market Share by Application

10 ASIA-PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

10.1 4SC AG
  10.1.1 Company Basic Information, Manufacturing Base and Competitors
  10.1.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.1.2.1 Product A
    10.1.2.2 Product B
  10.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.1.4 Main Business/Business Overview
10.2 AbbVie Inc.
  10.2.1 Company Basic Information, Manufacturing Base and Competitors
  10.2.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.2.2.1 Product A
    10.2.2.2 Product B
  10.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.2.4 Main Business/Business Overview
10.3 Actinium Pharmaceuticals, Inc.
  10.3.1 Company Basic Information, Manufacturing Base and Competitors
  10.3.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.3.2.1 Product A
    10.3.2.2 Product B
  10.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.3.4 Main Business/Business Overview
10.4 Agios Pharmaceuticals, Inc.
  10.4.1 Company Basic Information, Manufacturing Base and Competitors
  10.4.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.4.2.1 Product A
    10.4.2.2 Product B
  10.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.4.4 Main Business/Business Overview
10.5 Amgen Inc.
  10.5.1 Company Basic Information, Manufacturing Base and Competitors
  10.5.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.5.2.1 Product A
    10.5.2.2 Product B
  10.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.5.4 Main Business/Business Overview
10.6 Arog Pharmaceuticals, Inc.
  10.6.1 Company Basic Information, Manufacturing Base and Competitors
  10.6.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.6.2.1 Product A
    10.6.2.2 Product B
  10.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.6.4 Main Business/Business Overview
10.7 Array BioPharma Inc.
  10.7.1 Company Basic Information, Manufacturing Base and Competitors
  10.7.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.7.2.1 Product A
    10.7.2.2 Product B
  10.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.7.4 Main Business/Business Overview
10.8 Astellas Pharma Inc.
  10.8.1 Company Basic Information, Manufacturing Base and Competitors
  10.8.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.8.2.1 Product A
    10.8.2.2 Product B
  10.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.8.4 Main Business/Business Overview
10.9 Astex Pharmaceuticals, Inc.
  10.9.1 Company Basic Information, Manufacturing Base and Competitors
  10.9.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.9.2.1 Product A
    10.9.2.2 Product B
  10.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.9.4 Main Business/Business Overview
10.10 AstraZeneca Plc
  10.10.1 Company Basic Information, Manufacturing Base and Competitors
  10.10.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    10.10.2.1 Product A
    10.10.2.2 Product B
  10.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  10.10.4 Main Business/Business Overview
10.11 AVEO Pharmaceuticals, Inc.
10.12 BioLineRx, Ltd.
10.13 Boehringer Ingelheim GmbH
10.14 Boston Biomedical, Inc.
10.15 Bristol-Myers Squibb Company
10.16 Calithera Biosciences, Inc.
10.17 Celgene Corporation
10.18 Cornerstone Pharmaceuticals, Inc.
10.19 CTI BioPharma Corp.

11 RELAPSED ACUTE MYELOID LEUKEMIA DRUG MANUFACTURING COST ANALYSIS

11.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
  11.1.1 Key Raw Materials
  11.1.2 Price Trend of Key Raw Materials
  11.1.3 Key Suppliers of Raw Materials
  11.1.4 Market Concentration Rate of Raw Materials
11.2 Proportion of Manufacturing Cost Structure
  11.2.1 Raw Materials
  11.2.2 Labor Cost
  11.2.3 Manufacturing Expenses
11.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug

12 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

12.1 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
12.2 Upstream Raw Materials Sourcing
12.3 Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
12.4 Downstream Buyers

13 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

13.1 Marketing Channel
  13.1.1 Direct Marketing
  13.1.2 Indirect Marketing
  13.1.3 Marketing Channel Development Trend
13.2 Market Positioning
  13.2.1 Pricing Strategy
  13.2.2 Brand Strategy
  13.2.3 Target Client
13.3 Distributors/Traders List

14 MARKET EFFECT FACTORS ANALYSIS

14.1 Technology Progress/Risk
  14.1.1 Substitutes Threat
  14.1.2 Technology Progress in Related Industry
14.2 Consumer Needs/Customer Preference Change
14.3 Economic/Political Environmental Change

15 ASIA-PACIFIC RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET FORECAST (2018-2025)

15.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume, Revenue and Price Forecast (2018-2025)
  15.1.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate Forecast (2018-2025)
  15.1.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate Forecast (2018-2025)
  15.1.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Price and Trend Forecast (2018-2025)
15.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume, Revenue and Growth Rate Forecast by Region (2018-2025)
  15.2.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume and Growth Rate Forecast by Region (2018-2025)
  15.2.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate Forecast by Region (2018-2025)
  15.2.3 China Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate Forecast (2018-2025)
  15.2.4 Japan Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate Forecast (2018-2025)
  15.2.5 South Korea Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate Forecast (2018-2025)
  15.2.6 Taiwan Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate Forecast (2018-2025)
  15.2.7 India Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate Forecast (2018-2025)
  15.2.8 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate Forecast (2018-2025)
  15.2.9 Australia Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate Forecast (2018-2025)
15.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Price Forecast by Type (2018-2025)
  15.3.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Type (2018-2025)
  15.3.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Type (2018-2025)
  15.3.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Price Forecast by Type (2018-2025)
15.4 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Application (2018-2025)

16 RESEARCH FINDINGS AND CONCLUSION

17 APPENDIX

17.1 Methodology/Research Approach
  17.1.1 Research Programs/Design
  17.1.2 Market Size Estimation
  17.1.3 Market Breakdown and Data Triangulation
17.2 Data Source
  17.2.1 Secondary Sources
  17.2.2 Primary Sources
17.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.


LIST OF TABLES AND FIGURES

Figure Product Picture of Relapsed Acute Myeloid Leukemia Drug
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (Product Category) in 2017
Figure aNK Program Product Picture
Figure AT-9283 Product Picture
Figure BI-836858 Product Picture
Figure binimetinib Product Picture
Figure BL-8040 Product Picture
Figure Others Product Picture
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Application (2013-2025)
Figure Asia-Pacific Sales Market Share of Relapsed Acute Myeloid Leukemia Drug by Application in 2017
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) by Region (2013-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure India Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Australia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) and Growth Rate (2013-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Major Players Product Sales Volume (K Pcs)(2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share by Players/Suppliers (2013-2018)
Figure 2017 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share by Players/Suppliers
Figure 2017 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share by Players/Suppliers
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Major Players Product Revenue (Million USD) 2013-2018
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) by Players/Suppliers (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share by Players
Figure 2017 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share by Players
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Type (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2013-2018)
Figure Sales Market Share of Relapsed Acute Myeloid Leukemia Drug by Type (2013-2018)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Type (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Relapsed Acute Myeloid Leukemia Drug by Type (2013-2018)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate by Type (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) and Market Share by Region (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share by Region (2013-2018)
Figure Sales Market Share of Relapsed Acute Myeloid Leukemia Drug by Region (2013-2018)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region in 2017
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Region (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share (%) by Region (2013-2018)
Figure Revenue Market Share of Relapsed Acute Myeloid Leukemia Drug by Region (2013-2018)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in 2017
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) and Market Share by Application (2013-2018)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Application (2013-2018)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2013-2018)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Trend (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type in 2017
Table China Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Applications (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application in 2017
Figure Japan Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2018)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Trend (2013-2018)
Table Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2018)
Table Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2013-2018)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type in 2017
Table Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Applications (2013-2018)
Table Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application (2013-2018)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application in 2017
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2018)
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Trend (2013-2018)
Table South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2018)
Table South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2013-2018)
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type in 2017
Table South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Applications (2013-2018)
Table South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application (2013-2018)
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application in 2017
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2018)
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Trend (2013-2018)
Table Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2018)
Table Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2013-2018)
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type in 2017
Table Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Applications (2013-2018)
Table Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application (2013-2018)
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application in 2017
Figure India Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure India Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2018)
Figure India Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Trend (2013-2018)
Table India Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2018)
Table India Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2013-2018)
Figure India Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type in 2017
Table India Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Application (2013-2018)
Table India Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application (2013-2018)
Figure India Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application in 2017
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2018)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Trend (2013-2018)
Table Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2018)
Table Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2013-2018)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type in 2017
Table Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Applications (2013-2018)
Table Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application (2013-2018)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application in 2017
Figure Australia Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Australia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2018)
Figure Australia Relapsed Acute Myeloid Leukemia Drug Sales Price (USD/Pcs) Trend (2013-2018)
Table Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Type (2013-2018)
Table Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2013-2018)
Figure Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type in 2017
Table Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) by Applications (2013-2018)
Table Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application (2013-2018)
Figure Australia Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Application in 2017
Table 4SC AG Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales Market Share in Asia-Pacific (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Revenue Market Share in Asia-Pacific (2013-2018)
Table AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price (USD/Pcs) Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Relapsed Acute Myeloid Leukemia Drug
Figure Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
Figure Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
Table Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
Table Major Buyers of Relapsed Acute Myeloid Leukemia Drug
Table Distributors/Traders List
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) and Trend Forecast (2018-2025)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume (K Pcs) Forecast by Region (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share Forecast by Region (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share Forecast by Region in 2025
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) Forecast by Region (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Region (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Region in 2025
Figure China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure South Korea Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure India Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure India Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Australia Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Australia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Type (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Type (2018-2025)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) Forecast by Type (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Type (2018-2025)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) Forecast by Type (2018-2025)
Table Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Application (2018-2025)
Figure Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Application (2018-2025)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories